OR WAIT null SECS
July 17, 2019
Catalent Biologics has entered into a long-term strategic agreement to develop and manufacture an AveXis gene therapy treatment for spinal muscular atrophy (SMA), Zolgensma.
July 16, 2019
Kite, a Gilead company, announced plans to build a new facility for the development and manufacturing of the starting material for the production of cell therapies, viral vectors.
July 02, 2019
Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.
July 01, 2019
Novavax will sell two Maryland-based vaccine development and manufacturing facilities for Catalent’s expanding gene therapy footprint.
June 19, 2019
IVERIC bio and Catalent Biologics have entered into a strategic manufacturing agreement for gene therapy product candidates to treat orphan inherited retinal diseases.
The companies have signed a strategic multi-year manufacturing agreement for the future commercial production a late-phase investigational cell therapy.
June 07, 2019
The $10-million investment will include a 500-L single-use perfusion bioreactor and seven patented downstream processing units.
May 30, 2019
A new facility to be built in the Philadelphia Navy Yard will support commercial production for autologous tumor-infiltrating lymphocyte cell therapy products from Iovance Biotherapeutics.
May 15, 2019
GE Healthcare launches Chronicle GMP-compliant automation software for cell therapy manufacturing.
The highly customized nature of cell and gene therapy production means that manufacturing innovations for one therapy may not be easily transferable to others.